Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200505 | 1.00 | HTR6 (0.51) | HTR6GAANOX1MEN1CYP2D6 | |
| SCHEMBL6201833 | 1.00 | HTR6 (0.51) | HTR6GAANOX1MEN1CYP2D6 | |
| SCHEMBL6218260 | 1.00 | HTR6 (0.51) | HTR6GAANOX1MEN1CYP2D6 | |
| SCHEMBL6201912 | 1.00 | HTR6 (0.51) | HTR6GAANOX1MEN1CYP2D6 | |
| SCHEMBL6198477 | 1.00 | HTR6 (0.51) | HTR6GAANOX1MEN1CYP2D6 | |
| SCHEMBL6202313 | 0.89 | HTR6 (0.54) | HTR6DRD3HTR2C | |
| SCHEMBL6220923 | 0.89 | HTR6 (0.54) | HTR6DRD3HTR2C | |
| SCHEMBL6198846 | 0.89 | HTR6 (0.54) | HTR6DRD3HTR2C | |
| SCHEMBL6201008 | 0.89 | HTR6 (0.54) | HTR6DRD3HTR2C | |
| SCHEMBL6202015 | 0.89 | HTR6 (0.54) | HTR6DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351961-B1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-27 | — | — | EP | claimed |
| US-20020160999-A1 | Substituted indolines | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | claimed |
| EP-1351961-B1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1351961-A1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020160999-A1 | Substituted indolines | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002060903-A1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160999-A1 | Substituted indolines | TPH1, TPH2, NLN | HTR6 16/4885GAA 971/4885NOX1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.